Radiological-Nuclear Biodosimetry and Countermeasure Product Development Grants

Biodosimetry - Radiation Sickness Countermeasures
Credit: Shutterstock, adapted.

In support of rapid development of safe and effective radiological/nuclear medical countermeasures for clinical use under emergency situations, the National Institute of Allergy and Infectious Diseases (NIAID) is seeking new or renewal Small Business Innovation Research (SBIR) grant applications.

This funding will support non-clinical and preclinical product development activities to advance new medical countermeasures in preparation for, Phase I clinical trial safety studies, Good Laboratory Practices (GLP) animal model pivotal efficacy studies, and FDA licensure.

Highlighted priority areas of product development include:

  • Minimally invasive or non-invasive biodosimetry devices useful for emergency triage that can rapidly and accurately distinguish individuals who need treatment from those who do not, and that can identify and measure internal and external exposure.
  • Medical products and regimens that mitigate and/or treat radiation injury post-exposure with emphasis on broad activity, ease of administration in a mass casualty and emergency scenario; safety; and long shelf-life.
  • Medical products and regimens that accelerate the removal of inhaled, insoluble particles containing radionuclides from the lungs. Radionuclide decorporation agents that facilitate elimination of a range of radionuclides from the body or blocking agents that prevent the absorption of radionuclides in the body.
  • New medical product formulations that can be easily administered to civilian populations, including special populations (e.g. infants, children, elderly, and the immunocompromised) in emergency situations.

Budgets up to $300,000 total costs per year for Phase I and up to $1,000,000 total costs per year for Phase II may be requested.

Additional details are available via Funding Opportunity Announcement (FOA) Number PA-18-525. The open date for applications is 5 March 2018.

From Our Partners

More From Global Biodefense